Top Page
Terragen Holdings Ltd
(Sydney:TGH)
Terragen Holdings Ltd (TGH) vs. iShares MSCI Australia ETF (EWA)
Terragen Holdings Ltd Business Overview & Revenue Model
Terragen Holdings Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.62M | 1.62M | 2.14M | 3.28M | 2.89M | 3.65M |
| Gross Profit | 792.23K | 792.23K | 2.06M | 3.21M | 2.62M | 3.19M |
| EBITDA | -4.70M | -4.68M | -3.50M | -3.46M | -5.67M | -6.13M |
| Net Income | -3.72M | -3.72M | -3.01M | -3.23M | -5.41M | -6.10M |
Balance Sheet | ||||||
| Total Assets | 8.12M | 8.12M | 6.95M | 6.35M | 9.22M | 14.72M |
| Cash, Cash Equivalents and Short-Term Investments | 4.81M | 4.81M | 4.54M | 4.17M | 6.67M | 11.64M |
| Total Debt | 735.45K | 735.45K | 542.23K | 239.37K | 332.26K | 357.96K |
| Total Liabilities | 1.55M | 1.55M | 1.63M | 1.27M | 1.46M | 1.70M |
| Stockholders Equity | 6.57M | 6.57M | 5.32M | 5.08M | 7.76M | 13.02M |
Cash Flow | ||||||
| Free Cash Flow | -3.03M | -3.03M | -2.35M | -2.91M | -4.97M | -4.93M |
| Operating Cash Flow | -3.03M | -3.03M | -2.32M | -2.81M | -4.80M | -4.52M |
| Investing Cash Flow | -682.43K | -682.43K | -132.93K | -35.20K | -118.20K | -408.02K |
| Financing Cash Flow | 3.87M | 3.87M | 2.82M | 351.00K | -52.70K | 194.92K |
Terragen Holdings Ltd Technical Analysis
Terragen Holdings Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
52 Neutral | AU$32.66M | -7.76 | -25.50% | ― | -100.00% | -182.93% | |
50 Neutral | AU$31.38M | -14.26 | -41.21% | ― | 140.94% | 88.59% | |
46 Neutral | AU$9.04M | -1.59 | -217.79% | ― | ― | 43.46% | |
43 Neutral | AU$10.58M | -1.11 | -390.08% | ― | ― | 19.94% | |
39 Underperform | AU$12.63M | -2.81 | -62.66% | ― | -24.42% | -2.30% |
Terragen Holdings Ltd Corporate Events
Terragen Holdings Ltd, listed on the ASX under code TGH, has reported a change in its issued capital structure. The company has confirmed that 5 million options, previously on issue and exercisable at A$1.00 with an expiry date of 4 December 2025, have lapsed unexercised as of that date. The expiry of these options without conversion reduces the potential future dilution of existing shareholders and marginally simplifies Terragen’s capital structure, although it does not directly affect current issued share capital or provide new funding to the company.
The most recent analyst rating on (AU:TGH) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Terragen Holdings Ltd stock, see the AU:TGH Stock Forecast page.
Terragen Holdings Limited has announced the expiry of 2,000,000 unexercised options (ASX code TGHAU) that were due to expire on 4 December 2025 with an exercise price of A$0.50. The lapse of these options slightly reduces the company’s potential future share dilution but has no immediate impact on its existing issued capital, reflecting a routine adjustment to its capital structure rather than a change in underlying operations.
The most recent analyst rating on (AU:TGH) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Terragen Holdings Ltd stock, see the AU:TGH Stock Forecast page.
Terragen Holdings Limited has confirmed the expiry of a tranche of unexercised options listed on the ASX. The company reported that 1,000,000 options, exercisable at A$0.25 and due to expire on 4 December 2025 under the code TGHAT, have lapsed without being converted into shares, resulting in a reduction of potential future dilution for existing shareholders but no immediate change to the company’s issued capital.
The most recent analyst rating on (AU:TGH) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Terragen Holdings Ltd stock, see the AU:TGH Stock Forecast page.
Terragen Holdings Limited has confirmed the expiry of a tranche of unexercised options listed on the ASX. The company reported that 1,000,000 options, exercisable at A$0.25 and due to expire on 4 December 2025 under the code TGHAT, have lapsed without being converted into shares, resulting in a reduction of potential future dilution for existing shareholders but no immediate change to the company’s issued capital.
The most recent analyst rating on (AU:TGH) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Terragen Holdings Ltd stock, see the AU:TGH Stock Forecast page.
Terragen Holdings Limited has received a $989,242 R&D tax incentive from the Australian Taxation Office for the 2024/2025 financial year, which will bolster their cash reserves and support ongoing commercialisation and development efforts. This incentive underscores Terragen’s commitment to advancing its position in the agricultural industry by investing in innovative solutions that enhance productivity and environmental outcomes, benefiting stakeholders and contributing to agricultural decarbonisation.
The most recent analyst rating on (AU:TGH) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Terragen Holdings Ltd stock, see the AU:TGH Stock Forecast page.
Terragen Holdings Limited has updated its Securities Trading Policy to align with Listing Rule 12.10, reflecting good corporate governance practices. The revisions include clearer guidelines for employee access to sensitive information, updated closed periods to coincide with the release of the Appendix 4C report, and the inclusion of the Chairman in the prior notification clause. These changes are part of Terragen’s commitment to maintaining transparency and compliance, potentially impacting how stakeholders interact with the company’s securities.
The most recent analyst rating on (AU:TGH) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Terragen Holdings Ltd stock, see the AU:TGH Stock Forecast page.
Terragen Holdings Limited held its Annual General Meeting on November 20, 2025, where all resolutions were successfully passed. Key resolutions included the adoption of the remuneration report, election of Mike Barry as a director, approval of securities issuance under the incentive plan, ratification of prior employee options issuance, approval of an additional 10% placement facility, and the appointment of an auditor. These decisions reflect the company’s strategic focus on strengthening its governance and financial structure, potentially enhancing its market position and stakeholder confidence.
Terragen Holdings Limited presented a summary of its current activities and financial data, emphasizing its diversified portfolio in animal probiotics and biostimulants. The presentation, intended for informational purposes, highlighted the company’s strategic positioning in the biotechnology sector, although it did not serve as an investment offer or advice. Stakeholders are advised to consider the inherent risks and uncertainties associated with forward-looking statements contained in the presentation.
Terragen Holdings Limited has released an investor update highlighting its current activities and market positioning. The update emphasizes the company’s commitment to advancing its biotechnology offerings, particularly in animal probiotics and biostimulants, which are crucial for sustainable agriculture. While the presentation includes forward-looking statements, it primarily serves as an informational document rather than an investment guide.
Terragen Holdings Limited has announced a significant purchase order from Mort & Co Fertilisers for 70,000 litres of its Great Land Plus bio-stimulant, following successful product trials. This order is expected to boost Terragen’s GLP sales by 57% in 2026, with an estimated annual revenue of $700,000, reflecting the product’s alignment with sustainability and productivity goals in the agricultural sector.